Anavex to Present at the Alzheimer’s Association International Conference (AAIC) 2016

NEW YORK, NY – July 12, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that data related to ANAVEX…

Alzheimer’s Association International Conference 2016 (AAIC) – July 24, 2016

Event: Poster presentation: New Exploratory Alzheimer’s Drug ANAVEX 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients Date/Time: Sunday, July 24, 2016 9:30 a.m. to 10:30 a.m. EDT Location: Hall D/E, Metro Toronto Convention Centre, Toronto, ON